Perspective
Mar. 28, 2015
Sandoz to Amgen: 'We don't want to dance'
A recent ruling cleared the way for the first biosimilar of a biologic product sold in the United States. By Stephen M. Hankins
On March 19, U.S. District Judge Richard G. Seeborg denied Amgen Inc.'s request for a preliminary injunction barring a generic version of Neupogen, which had been approved by the U.S. Food and Drug Administration in early March. Amgen v. Sandoz, 14-04741 (N.D. Cal.).
This ruling cleared the way for the Sandoz companies to launch the first biosimilar of a biologic product sold in the United States. The ruling also created...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In